Biykem Bozkurt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5440425/publications.pdf

Version: 2024-02-01

245 papers 58,452 citations

81 h-index 219 g-index

266 all docs 266 docs citations

266 times ranked 52264 citing authors

#	Article	lF	Citations
1	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	2.8	7,017
2	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation, 2014, 129, S1-45.	1.6	4,842
3	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation, 2014, 129, S49-73.	1.6	2,823
4	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
5	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
6	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
7	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	2.8	2,256
8	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161.	1.6	2,130
9	2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation, 2014, 129, S102-38.	1.6	2,114
10	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of PatientsÂUndergoing Noncardiac Surgery. Journal of the American College of Cardiology, 2014, 64, e77-e137.	2.8	1,135
11	2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 2014, 130, 2354-2394.	1.6	938
12	2014 AHA/ACC guideline for the management of patients with valvular heart disease. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, e1-e132.	0.8	887
13	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation, 2014, 130, e278-333.	1.6	829
14	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774
15	Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor-α Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats. Circulation, 1998, 97, 1382-1391.	1.6	773
16	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR00000000000001063.	1.6	756
17	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation, 2014, 130, 1749-1767.	1.6	685
18	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380.	7.1	630

#	Article	IF	CITATIONS
19	Myocarditis With COVID-19 mRNA Vaccines. Circulation, 2021, 144, 471-484.	1.6	620
20	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. Circulation, 2014, 130, 2215-2245.	1.6	608
21	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. Journal of the American College of Cardiology, 2019, 73, e81-e192.	2.8	595
22	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
23	Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population With Heart Failure and Preserved Versus Reduced Ejection Fraction. Journal of the American College of Cardiology, 2012, 59, 998-1005.	2.8	578
24	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	2.8	549
25	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e698-e800.	1.6	536
26	Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e579-e646.	1.6	532
27	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of Cardiac Failure, 2017, 23, 628-651.	1.7	531
28	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e578-e622.	1.6	503
29	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016, 134, e282-93.	1.6	494
30	Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction. Circulation, 2008, 118, 2803-2810.	1.6	455
31	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: ExecutiveÂSummary. Journal of the American College of Cardiology, 2019, 73, 1494-1563.	2.8	452
32	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation, 2020, 141, 1903-1914.	1.6	448
33	Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA) Tj ETQq1	1 0.78431 2.8	l 4 rgBT/Overlo
34	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of the American College of Cardiology, 2015, 66, 403-469.	2.8	428
35	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2017, 135, e1054-e1091.	1.6	417
36	Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e56-e67.	1.6	400

#	Article	IF	CITATIONS
37	Basic mechanisms in heart failure: The cytokine hypothesis. Journal of Cardiac Failure, 1996, 2, 243-249.	1.7	392
38	Management of Patients With Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA) Tj ETQ	ηΟ Ο Ο rgBT /Ove	erlock 10 Tf
39	Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure. Circulation, 1999, 99, 3224-3226.	1.6	367
40	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Circulation, 2015, 132, 302-361.	1.6	364
41	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	1.7	362
42	Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. Circulation, 2001, 103, 1044-1047.	1.6	358
43	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	2.8	314
44	Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Journal of Cardiac Failure, 2020, 26, 370.	1.7	312
45	Cardiovascular Function and Treatment in \hat{I}^2 -Thalassemia Major. Circulation, 2013, 128, 281-308.	1.6	301
46	Venoarterial ECMO for Adults. Journal of the American College of Cardiology, 2019, 73, 698-716.	2.8	300
47	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 2016, 134, e535-e578.	1.6	285
48	2013 ACCF/AHA Guideline for the Management ofÂHeartÂFailure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	2.8	276
49	Sexual Activity and Cardiovascular Disease. Circulation, 2012, 125, 1058-1072.	1.6	270
50	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.8	249
51	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
52	2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e637-e697.	1.6	225
53	Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011) Tj ETQq1 1	0.784314 rgBT 2.8	Overlock 1 222
54	2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 1966-2011.	2.8	222

#	Article	IF	CITATIONS
55	2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play. Journal of the American College of Cardiology, 2022, 79, 1717-1756.	2.8	220
56	Prevalence, Morbidity, and Mortality of Heart Failure–Related Hospitalizations in Children in the United States: A Population-Based Study. Journal of Cardiac Failure, 2012, 18, 459-470.	1.7	216
57	Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. Journal of the American College of Cardiology, 2003, 41, 211-214.	2.8	204
58	Intravenous immune globulin in the therapy of peripartum cardiomyopathy. Journal of the American College of Cardiology, 1999, 34, 177-180.	2.8	198
59	Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure. Circulation: Heart Failure, 2011, 4, 53-58.	3.9	172
60	Relationship of Hemoglobin A1C and Mortality in Heart Failure Patients With Diabetes. Journal of the American College of Cardiology, 2009, 54, 422-428.	2.8	171
61	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). Journal of Cardiac Failure, 2011, 17, 634-642.	1.7	171
62	Biomarkers of inflammation in heart failure. Heart Failure Reviews, 2010, 15, 331-341.	3.9	169
63	Management of Patients With Atrial Fibrillation (Compilation of 2006 ACCF/AHA/ESC and 2011) Tj ETQq1 1 0.784	314 rgBT	lOverlock 1 166
64	Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System. Circulation, 2016, 133, 1426-1428.	1.6	166
65	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. Journal of Nuclear Cardiology, 2015, 22, 162-215.	2.1	163
66	2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vascular Medicine, 2017, 22, NP1-NP43.	1.5	162
67	Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System. Journal of the American College of Cardiology, 2016, 67, 1572-1574.	2.8	154
68	Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization. Circulation: Heart Failure, 2020, 13, e006513.	3.9	154
69	Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovascular Research, 2002, 53, 822-830.	3.8	152
70	2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 61, 992-1025.	2.8	148
71	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. American Journal of Cardiology, 2015, 115, 21-26.	1.6	134
72	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR000000000000000000000000000000000000	1.6	133

#	Article	lF	Citations
73	The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey. Circulation, 2014, 130, 1208-1217.	1.6	120
74	Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves. Circulation, 2016, 133, 680-686.	1.6	111
75	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	7.1	105
76	Cardiac Rehabilitation for Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1454-1469.	2.8	102
77	Acute Bacterial Pneumonia is Associated With the Occurrence of Acute Coronary Syndromes. Medicine (United States), 2009, 88, 154-159.	1.0	101
78	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. Journal of Cardiac Failure, 2002, 8, 390-398.	1.7	97
79	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, e5-e23.	0.8	97
80	Delayed recovery in peripartum cardiomyopathy: an indication for longâ€ŧerm followâ€up and sustained therapy. European Journal of Heart Failure, 2012, 14, 895-901.	7.1	90
81	2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: Executive Summary. Journal of the American College of Cardiology, 2014, 64, 2373-2405.	2.8	88
82	Lifestyle Modifications for PreventingÂand Treating HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2391-2405.	2.8	87
83	STâ€elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of STâ€elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.	1.7	85
84	Catheterization and Cardiovascular Interventions, 2016, 87, 1001-1019. Pre-Morbid Body Mass Index and MortalityÂAfter Incident Heart Failure. Journal of the American College of Cardiology, 2014, 64, 2743-2749.	2.8	83
85	Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2010, 105, 373-377.	1.6	81
86	Comparison of Morbidity in Women Versus Men With Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 2006, 97, 1228-1231.	1.6	78
87	Obesity as a prognostic factor in chronic symptomatic heart failure. American Heart Journal, 2005, 150, 1233-1239.	2.7	77
88	Evaluation for Heart Transplantation andÂLVAD Implantation. Journal of the American College of Cardiology, 2020, 75, 1471-1487.	2.8	77
89	An overview of tumor necrosis factor \hat{l}_{\pm} and the failing human heart. Current Opinion in Cardiology, 1999, 14, 206.	1.8	77
90	Heart Failure in Women. Methodist DeBakey Cardiovascular Journal, 2021, 13, 216.	1.0	76

#	Article	IF	CITATIONS
91	2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to) Tj ETQq1 1	0,784314 2:2	rgBT /Over
92	Outcomes, 2021, 14, e000102. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy. JACC: Heart Failure, 2016, 4, 380-388.	4.1	68
93	Prognostic Significance of Hyponatremia Among Ambulatory Patients With Heart Failure and Preserved and Reduced Ejection Fractions. American Journal of Cardiology, 2014, 113, 1834-1838.	1.6	67
94	ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records. Circulation, 2011, 124, 103-123.	1.6	66
95	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
96	Cardiac Surgery During the Coronavirus Disease 2019 Pandemic: Perioperative Considerations and Triage Recommendations. Journal of the American Heart Association, 2020, 9, e017042.	3.7	63
97	Does the Level of Experience of Residents Affect Outcomes of Coronary Artery Bypass Surgery?. Annals of Thoracic Surgery, 2009, 87, 1127-1134.	1.3	62
98	Sex Differences in Heart Failure. Journal of Cardiac Failure, 2022, 28, 477-498.	1.7	62
99	Cardiac remodeling as a consequence and cause of progressive heart failure. Clinical Cardiology, 1998, 21, 14-19.	1.8	61
100	New Therapeutics for Chronic Heart Failure. Annual Review of Medicine, 2002, 53, 59-74.	12.2	60
101	Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship. American Heart Journal, 2011, 161, 567-573.	2.7	60
102	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2016, 22, 659-669.	1.7	59
103	Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2014, 2, 412-421.	4.1	58
104	Reduction in BNP Levels With Treatment of Decompensated Heart Failure and Future Clinical Events. Journal of Cardiac Failure, 2009, 15, 293-299.	1.7	55
105	2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease. Circulation, 2012, 125, 395-467.	1.6	55
106	Provider Type and Quality of Outpatient Cardiovascular Disease Care. Journal of the American College of Cardiology, 2015, 66, 1803-1812.	2.8	54
107	Cytokines in Heart Failure: Pathogenetic Mechanisms and Potential Treatment. Proceedings of the Association of American Physicians, 1999, 111, 423-428.	2.0	53
108	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. International Journal of Cardiology, 2013, 168, 3741-3746.	1.7	52

#	Article	IF	CITATIONS
109	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. Hypertension, 2020, 76, 1350-1367.	2.7	46
110	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership. Journal of the American College of Cardiology, 2021, 77, 2960-2972.	2.8	45
111	The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. American Journal of Surgery, 2008, 196, 720-725.	1.8	43
112	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. International Journal of Cardiology, 2017, 233, 61-66.	1.7	42
113	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	1.7	42
114	2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials. Journal of Nuclear Cardiology, 2015, 22, 1041-1144.	2.1	41
115	Programmable Bio-NanoChip Technology for the Diagnosis of Cardiovascular Disease at the Point of Care. Methodist DeBakey Cardiovascular Journal, 2021, 8, 6.	1.0	40
116	Chagas Cardiomyopathy is Associated With Higher Incidence of Stroke: A Meta-analysis of Observational Studies. Journal of Cardiac Failure, 2014, 20, 931-938.	1.7	39
117	Use of Biomarkers in the Management of Heart Failure. Circulation, 2003, 107, 1231-1233.	1.6	35
118	Cardiovascular Toxicity With Highly Active Antiretroviral Therapy: Review of Clinical Studies. Cardiovascular Toxicology, 2004, 4, 243-260.	2.7	35
119	Echocardiographic Changes During Treatment of Acute Decompensated Heart Failure: Insights From the ESCAPE Trial. Journal of Cardiac Failure, 2012, 18, 792-798.	1.7	35
120	Percutaneous Coronary Intervention vs. Coronary Artery Bypass Graft Surgery for Unprotected Left Main Coronary Artery Disease in the Drug-Eluting Stents Era. Circulation Journal, 2013, 77, 372-382.	1.6	35
121	High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories. Hypertension, 2015, 65, 78-84.	2.7	35
122	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 829-850.e1.	0.8	34
123	The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure. Journal of the American College of Cardiology, 2007, 50, 32-36.	2.8	33
124	Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease. Expert Systems With Applications, 2016, 54, 136-147.	7.6	33
125	Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. American Journal of Medicine, 2020, 133, 1293-1301.e1.	1.5	33
126	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. Journal of the American College of Cardiology, 2021, 77, 559-571.	2.8	31

#	Article	IF	CITATIONS
127	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. Journal of Cardiac Failure, 2002, 8, 306-314.	1.7	30
128	Barriers to Non-HDL Cholesterol Goal Attainment by Providers. American Journal of Medicine, 2011, 124, 876-880.e2.	1.5	30
129	Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 2384-2387.	2.8	30
130	2021 ACC/AHA Key Data Elements and Definitions for Heart Failure. Journal of the American College of Cardiology, 2021, 77, 2053-2150.	2.8	29
131	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	1.7	29
132	Endpoints in HeartÂFailure DrugÂDevelopment. JACC: Heart Failure, 2020, 8, 429-440.	4.1	28
133	Redefining Myocardial Infarction: What is new in the ESC/ACCF/AHA/WHF Third Universal Definition of Myocardial Infarction?. Methodist DeBakey Cardiovascular Journal, 2021, 9, 169.	1.0	27
134	What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines. Current Cardiology Reports, 2018, 20, 39.	2.9	27
135	Digoxin and Clinical Outcomes in Systolic Heart Failure Patients on Contemporary Background Heart Failure Therapy. American Journal of Cardiology, 2008, 102, 1356-1360.	1.6	26
136	Diagnosis and management of acute heart failure. Anatolian Journal of Cardiology, 2015, 15, 860-889.	0.9	26
137	American Heart Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations. Journal of the American Heart Association, 2018, 7, e009271.	3.7	25
138	New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patientsâ€"A Matter of Time for Contractility. Journal of Cardiac Failure, 2012, 18, 183-193.	1.7	24
139	ACC/AHA 2013 Methodology for Developing Clinical Data Standards. Journal of the American College of Cardiology, 2014, 63, 2323-2334.	2.8	24
140	Breastfeeding, Cellular Immune Activation, andÂMyocardial Recovery inÂPeripartumÂCardiomyopathy. JACC Basic To Translational Science, 2019, 4, 291-300.	4.1	24
141	Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions. Current Cardiology Reviews, 2014, 10, 317-326.	1.5	24
142	The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scandinavian Journal of Infectious Diseases, 2009, 41, 511-514.	1.5	23
143	Worsening renal function is not associated with response to treatment in acute heart failure. International Journal of Cardiology, 2013, 167, 1912-1917.	1.7	23
144	Recurrent low-level Troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. International Journal of Cardiology, 2013, 166, 394-398.	1.7	23

#	Article	IF	CITATIONS
145	Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2018, 7, .	3.7	23
146	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	2.3	23
147	Effect of the Soluble TNFâ€Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability. Clinical and Translational Science, 2008, 1, 142-145.	3.1	22
148	Impact of Alpha 1-Adrenergic Antagonist Use for Benign Prostatic Hypertrophy on Outcomes in Patients With Heart Failure. American Journal of Cardiology, 2009, 104, 270-275.	1.6	22
149	Usefulness of the Sum of Pulmonary Capillary Wedge Pressure and Right Atrial Pressure as a Congestion Index that Prognosticates Heart Failure Survival (from the Evaluation Study of) Tj ETQq1 1 0.784314 of Cardiology. 2016. 118. 854-859.	rgBT /Over	rlock 10 Tf
150	The role of anti-cytokine therapy in the failing heart. Heart Failure Reviews, 2001, 6, 143-151.	3.9	19
151	Digoxin treatment in heart failure — Unveiling risk by cluster analysis of DIG data. International Journal of Cardiology, 2011, 150, 264-269.	1.7	19
152	Trials on the Effect of Cardiac Resynchronization on Arterial Blood Pressure in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 561-568.	1.6	19
153	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure – A Pilot Study. Journal of Obesity & Weight Loss Therapy, 2012, 02, 1-8.	0.1	19
154	Myocardial Injury, Obesity, and the Obesity Paradox. JACC: Heart Failure, 2017, 5, 56-63.	4.1	19
155	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. International Journal of Cardiology, 2014, 172, 239-241.	1.7	18
156	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. European Journal of Preventive Cardiology, 2017, 24, 628-638.	1.8	17
157	Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. American Journal of Cardiology, 2017, 119, 2030-2034.	1.6	17
158	ACC/AHA 2013 Methodology for Developing Clinical Data Standards: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation, 2014, 129, 2346-2357.	1.6	16
159	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG AD) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	16
160	Substance and Substrate. Circulation, 2020, 141, 362-366.	1.6	16
161	Shortness of Breath. Circulation, 2003, 108, e11-3.	1.6	15
162	Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study. Journal of Cardiac Failure, 2018, 24, 33-42.	1.7	15

#	Article	IF	CITATIONS
163	Response to Ryan and Parwani: Heart Failure Patients With Low Blood Pressure: How Should We Manage Neurohormonal Blocking Drugs?. Circulation: Heart Failure, 2012, 5, 820-821.	3.9	14
164	Early Experience of a Transcatheter Aortic Valve Program at a Veterans Affairs Facility. JAMA Surgery, 2013, 148, 1087.	4.3	13
165	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376.	2.2	13
166	Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap. American Heart Journal Plus, 2022, 13, 100093.	0.6	13
167	Tumor necrosis factor-? and tumor necrosis factor receptors in human heart failure. Heart Failure Reviews, 1996, 1, 211-219.	3.9	12
168	The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. Journal of Cardiac Failure, 2008, 14, 590-595.	1.7	12
169	Peripartum Cardiomyopathy: A Contemporary Review. Methodist DeBakey Cardiovascular Journal, 2021, 9, 38.	1.0	12
170	Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. American Journal of Perinatology, 2019, 36, 476-483.	1.4	12
171	Establishment of a transcatheter aortic valve program and heart valve team at a Veterans Affairs facility. American Journal of Surgery, 2012, 204, 643-648.	1.8	11
172	Patient Characteristics and Outcomes of Type 2 Myocardial Infarction During Heart Failure Hospitalizations in the United States. American Journal of Medicine, 2021, 134, 1371-1379.e2.	1.5	10
173	Medical and surgical therapy for cardiac remodeling. Current Opinion in Cardiology, 1999, 14, 196.	1.8	10
174	Cardiovascular risk and complications associated with COVID-19. American Journal of Cardiovascular Disease, 2020, 10, 479-489.	0.5	10
175	Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 2022, 8, e01.	3.0	10
176	Acoustic Detection of Coronary Occlusions before and after Stent Placement Using an Electronic Stethoscope. Entropy, 2016, 18, 281.	2,2	9
177	Target Dose Versus Maximum Tolerated Dose in Heart Failure. JACC: Heart Failure, 2019, 7, 359-362.	4.1	9
178	2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography. Journal of the American Society of Echocardiography, 2019, 32, 1161-1248.	2.8	8
179	Central venous pressure and pulmonary capillary wedge pressure: fresh clinical perspectives from a new model of discordant and concordant heart failure. Texas Heart Institute Journal, 2011, 38, 627-38.	0.3	8
180	Where Do We Currently Stand With Advice On Hormone Replacement Therapy For Women?. Methodist DeBakey Cardiovascular Journal, 2010, 6, 21-25.	1.0	6

#	Article	IF	Citations
181	Transcatheter Aortic Valve Replacement as a Treatment for Late Apicoaortic Conduit Obstruction in a Patient With Severe Aortic Stenosis. Circulation, 2013, 127, e491-4.	1.6	6
182	Heart Failure Site-Based Research inÂthe United States. JACC: Heart Failure, 2019, 7, 431-438.	4.1	6
183	Enkephalins and the Opioid System of the Heart. Circulation: Heart Failure, 2019, 12, e005851.	3.9	6
184	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation: Cardiovascular Quality and Outcomes, 0, , .	2.2	5
185	Treatment of patients with heart failure and preserved ejection fraction. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 516-528.	0.9	4
186	Does the use of bilateral internal mammary artery grafts impact survival of veterans undergoing coronary artery bypass surgery?. American Journal of Surgery, 2008, 196, 726-731.	1.8	4
187	Randomized Trial of Aldosterone AntagonisM in Diastolic Heart Failure (RAAM-DHF). Journal of Cardiac Failure, 2010, 16, S7.	1.7	4
188	The Treatment of Heart Failure in the 21st Century: Is the Glass Half Empty or Half Full?. Methodist DeBakey Cardiovascular Journal, 2021, 9, 3.	1.0	4
189	The Assessment of Stent Effectiveness Using a Wearable Beamforming MEMS Microphone Array System. IEEE Journal of Translational Engineering in Health and Medicine, 2016, 4, 1-10.	3.7	4
190	Proinflammatory TH17 cytokine activation, disease severity and outcomes in peripartum cardiomyopathy. International Journal of Cardiology, 2021, 339, 93-98.	1.7	4
191	Cardiac rehabilitation in heart failure: Indications for exercise training based on heart failure phenotype. Progress in Cardiovascular Diseases, 2021, , .	3.1	4
192	Outcomes and Resource Utilization in Patients Hospitalized with Gastrointestinal Bleeding Complicated by Types 1 and 2 Myocardial Infarction. American Journal of Medicine, 2022, 135, 975-983.e2.	1.5	4
193	Cost of Heart Failure Admissions in Children in the United States. Journal of Cardiac Failure, 2010, 16, 586.	1.7	3
194	Fourth Annual Go Red for Women Issue. Circulation, 2020, 141, 499-500.	1.6	3
195	Sixth Annual Go Red for Women Issue. Circulation, 2022, 145, 489-490.	1.6	3
196	An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. Cardiovascular Drugs and Therapy, 2022, , 1.	2.6	3
197	Telehealth in Heart Failure. Heart Failure Clinics, 2022, 18, 213-221.	2.1	3
198	Guiding Left Ventricular Lead Positioning and Refining Ability to Predict Response and Nonresponse to Cardiac Resynchronization Therapy Using dP/dtmax. Journal of the American College of Cardiology, 2011, 58, 1137-1139.	2.8	2

#	Article	IF	CITATIONS
199	Heart Failure as a Consequence of Dilated Cardiomyopathy. , 2011, , 372-394.		2
200	Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. Respiratory Research, 2015, 16, 126.	3.6	2
201	The 2017 AHA/ACC Performance and Quality Measures for Patients With Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 659.	6.1	2
202	Highâ€Sensitivity Cardiac Troponin: From Patient Phenotypes to Clinical Events in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e011174.	3.7	2
203	Update in recent clinical trials in heart failure. Current Opinion in Cardiology, 2019, 34, 307-314.	1.8	2
204	Factor Xa Inhibition, A New Strategy forÂPrevention of Adverse Cardiac Remodeling in EarlyÂStages?. JACC Basic To Translational Science, 2020, 5, 84-87.	4.1	2
205	Public perception of heart failure on twitter: A sentiment analysis. Progress in Cardiovascular Diseases, 2021, 68, 91-93.	3.1	2
206	Progressive dehiscence and dynamic compression of an aortic root homograft: Detection and characterization by transesophageal echocardiography. American Heart Journal, 1996, 132, 1070-1073.	2.7	1
207	Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure. Journal of Cardiac Failure, 2010, 16, S83-S84.	1.7	1
208	Update: Shortness of Breath. Circulation, 2014, 129, e447-9.	1.6	1
209	Third Annual Go Red for Women Issue. Circulation, 2019, 139, 999-1000.	1.6	1
210	Impact of a Resident-Centered Interprofessional Quality Improvement Intervention on Acute Care Length of Stay. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2019, 41, 212-219.	0.7	1
211	Heart Failure as a Consequence of Dilated Cardiomyopathy. , 2020, , 269-287.e2.		1
212	Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. Annals of Pharmacotherapy, 2021, 55, 805-813.	1.9	1
213	Fifth Annual Go Red for Women Issue. Circulation, 2021, 143, 613-614.	1.6	1
214	Abstract 18749: Body Mass Index, Leptin, and Recovery in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. Circulation, 2015, 132, .	1.6	1
215	WORSENING RENAL FUNCTION IN ACUTE DECOMPENSATED HEART FAILURE: A BAD SIGN, OR MAYBE NOT?. Transactions of the American Clinical and Climatological Association, 2019, 130, 41-50.	0.5	1
216	Women leaders: transforming the culture in cardiology. Open Heart, 2022, 9, e001967.	2.3	1

#	Article	IF	Citations
217	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43.	0.0	1
218	Biomarkers of Inflammation. , 2006, , 295-318.		0
219	Thiazolidinediones Are Not Associated with Increased Risk of Heart Failure Hospitalizations in Ambulatory Patients with Diabetes Mellitus and Heart Failure. Journal of Cardiac Failure, 2006, 12, S93.	1.7	0
220	Aldosterone Antagonism in the Pharmacological Management of Chronic Heart Failure., 0,, 82-103.		0
221	Mechanisms of idiopathic dilated cardiomyopathies. Current Opinion in Organ Transplantation, 2006, 11, 553-559.	1.6	0
222	Effect of Digoxin on Clinical Outcomes in Patients on Contemporary Heart Failure Therapy. Journal of Cardiac Failure, 2008, 14, S100.	1.7	0
223	Improved propensity matching for heart failure using neural gas and self-organizing maps. , 2009, , .		0
224	Unsupervised cluster analysis and mortality risk in the Digitalis Investigation Group (DIG) trial of heart failure. , 2009, , .		0
225	Hemoglobin Drop during Hospitalization Predicts Poor Survival in Anemic Patients with Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2009, 15, S97-S98.	1.7	0
226	Cardiac Resynchronization Therapy in Reversing "Decapitated Hypertension―– A Meta-Analysis. Journal of Cardiac Failure, 2009, 15, S101-S102.	1.7	0
227	Futility of Digoxin in a Sub-Population of Heart Failure Patients – A Cluster Analysis of DIG Data. Journal of Cardiac Failure, 2009, 15, S104.	1.7	0
228	Digoxin and Other Positive Inotropic Agents. , 2010, , 171-175.		0
229	Ca2+/Calmodulin Dependent Protein Kinase II Phosphorylation of RyR2 Alters the Force-Frequency Relationship in Mice. Journal of Cardiac Failure, 2011, 17, S32.	1.7	0
230	Lack of Association of Changes in BNP with Cardiorenal Syndrome during Treatment of Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2011, 17, S91.	1.7	0
231	Lower Heart Rate Associated With Improved Outcomes in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2012, 18, S87.	1.7	0
232	Hyperacute T-waves: Wolff-Parkinson-White Pattern or Acute Coronary Syndrome?. Journal of Emergency Medicine, 2013, 44, 332-335.	0.7	0
233	Heart Failure Evaluation and Long-Term Management. , 2014, , 172-184.		0
234	SAFETY AND EFFECTIVENESS OF BALLOON AORTIC VALVULOPLASTY FOR SEVERE AORTIC STENOSIS IN THE CONTEMPORARY ERA. Journal of the American College of Cardiology, 2014, 63, A1746.	2.8	0

#	Article	IF	CITATIONS
235	No Increase in Mortality Seen with \hat{l}^2 -blocker Treatment in Heart Failure Patients with Cocaine Use. Journal of Cardiac Failure, 2015, 21, S120.	1.7	0
236	Heart Failure Society of America Research Network Survey. Journal of Cardiac Failure, 2018, 24, S9.	1.7	O
237	Differences between Academic and Non-Academic Institutions in Heart Failure Clinical Trials in North America: Insights from the HFSA Research Network Survey. Journal of Cardiac Failure, 2019, 25, S76-S77.	1.7	0
238	President's Message. Journal of Cardiac Failure, 2020, 26, 905-906.	1.7	0
239	The Role of Anti-Cytokine Therapy in the Failing Heart. Developments in Cardiovascular Medicine, 2001, , 83-91.	0.1	O
240	The clinical experience with anti-cytokine therapy in heart failure. , 2003, , 95-110.		0
241	Abstract 19771: Persistent Thrombocytopenia after Myocardial Infarction is Associated with Increased Short- and Long-Term Mortality. Circulation, 2014, 130, .	1.6	O
242	On the Shoulders of Witnesses: A Conversation With Biykem Bozkurt, MD, PhD. Circulation, 2022, 145, 491-495.	1.6	0
243	Outcomes of Hospitalizations With Septic Shock Complicated by Types 1 and 2 Myocardial Infarction. American Journal of Cardiology, 2022, , .	1.6	O
244	Abstract 18911: Relaxin-2 Levels and Early Myocardial Recovery in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. Circulation, 2015, 132, .	1.6	0
245	Abstract 16254: Heart Rate as a Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 132, .	1.6	O